BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis — Stella

Recruiting

Back to Systemic Light Chain Amyloidosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Key details

Phase

Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~21 participants

Started

September 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov